Nathalia Silva Carlos Oliveira

Dr. Nathalia Silva Carlos Oliveira

Pathology Department, Federal Fluminense University (UFF), Niterói, Rio de Janeiro, Brazil
orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2025 in Experimental and Molecular Pathology
Verified
Journal Article
Open access
LGLuiz Filipe Gonçalves-Oliveira
Luiz Filipe Gonçalves-Oliveira
JPJuliana Peixoto
Juliana Peixoto
BPBernardo A. S. Pereira
Bernardo A. S. Pereira
Nathalia Silva Carlos OliveiraNathalia Silva Carlos Oliveira
Nathalia Silva Carlos Oliveira
FCFlávia de Oliveira Cardoso
Flávia de Oliveira Cardoso
Carlos Roberto AlvesCarlos Roberto Alves
Carlos Roberto Alves
The development of innovative treatments for American Cutaneous Leishmaniasis is crucial due to severe side effects of current treatment and the emergence of non-responder parasites. To address such a challenge the incorporation of epoxy-α-lapachone (ELAP) into a microemulsion (ME), named ELAP-ME, represents a promising therapeutic approach. In previous studies, ELAP-ME demonstrated efficacy in controlling infection in the BALB/c-Leishmania (Leishmania) amazonensis model, advancing in the technology readiness level with a drug prototype. To further validate its potential as a drug prototype, the histopathological effects of ELAP-ME were investigated in healthy BALB/c mice as a preclinical approach stage. Mice were administered with a fixed dose of ELAP-ME microemulsion (∼7 μg/kg) and evaluated at different short-term after administration (4, 12, and 24 h). Histopathological analysis of the liver, kidney, lung, heart, and brain revealed only mild alterations. These findings confirm the low toxicity profile of ELAP-ME, highlighting its safety and supporting its continued advancement as a pharmacological alternative for the treatment of leishmaniasis.